747 related articles for article (PubMed ID: 32167173)
1. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.
Lung J; Lin YS; Yang YH; Chou YL; Shu LH; Cheng YC; Liu HT; Wu CY
J Med Virol; 2020 Jun; 92(6):693-697. PubMed ID: 32167173
[TBL] [Abstract][Full Text] [Related]
2. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Elfiky AA
Life Sci; 2020 May; 248():117477. PubMed ID: 32119961
[TBL] [Abstract][Full Text] [Related]
3. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
Banerjee A; Kanwar M; Maiti S
Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
[TBL] [Abstract][Full Text] [Related]
4. Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation.
Kato K; Honma T; Fukuzawa K
J Mol Graph Model; 2020 Nov; 100():107695. PubMed ID: 32702590
[TBL] [Abstract][Full Text] [Related]
5. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections.
Jin YH; Min JS; Jeon S; Lee J; Kim S; Park T; Park D; Jang MS; Park CM; Song JH; Kim HR; Kwon S
Phytomedicine; 2021 Jun; 86():153440. PubMed ID: 33376043
[TBL] [Abstract][Full Text] [Related]
6. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design.
Xu X; Liu Y; Weiss S; Arnold E; Sarafianos SG; Ding J
Nucleic Acids Res; 2003 Dec; 31(24):7117-30. PubMed ID: 14654687
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Zhang L; Zhou R
J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
[TBL] [Abstract][Full Text] [Related]
8. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
Khan A; Khan M; Saleem S; Babar Z; Ali A; Khan AA; Sardar Z; Hamayun F; Ali SS; Wei DQ
Interdiscip Sci; 2020 Sep; 12(3):335-348. PubMed ID: 32617855
[TBL] [Abstract][Full Text] [Related]
9. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
Elfiky AA
Life Sci; 2020 Jul; 253():117592. PubMed ID: 32222463
[TBL] [Abstract][Full Text] [Related]
10. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
11. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.
Aftab SO; Ghouri MZ; Masood MU; Haider Z; Khan Z; Ahmad A; Munawar N
J Transl Med; 2020 Jul; 18(1):275. PubMed ID: 32635935
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.
Jácome R; Campillo-Balderas JA; Ponce de León S; Becerra A; Lazcano A
Sci Rep; 2020 Jun; 10(1):9294. PubMed ID: 32518317
[TBL] [Abstract][Full Text] [Related]
13. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.
Kandeel M; Al-Nazawi M
Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634
[TBL] [Abstract][Full Text] [Related]
15. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
[TBL] [Abstract][Full Text] [Related]
16. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
17. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
[TBL] [Abstract][Full Text] [Related]
18. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes.
Kandeel M; Ibrahim A; Fayez M; Al-Nazawi M
J Med Virol; 2020 Jun; 92(6):660-666. PubMed ID: 32159237
[TBL] [Abstract][Full Text] [Related]
19. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
20. Potential Novel Thioether-Amide or Guanidine-Linker Class of SARS-CoV-2 Virus RNA-Dependent RNA Polymerase Inhibitors Identified by High-Throughput Virtual Screening Coupled to Free-Energy Calculations.
Jukič M; Janežič D; Bren U
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]